Join us at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Boston, MA!

Our booth will be open to greet visitors on November 10th and 11th at the Boston Exhibition and Convention Center! Stop by to chat with us (booth #743) to check out our latest model, service, and antibody assets offerings. Biocytogen has 2500+ models and extensive experience testing novel monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), and cell-based therapies in our highly specialized models. In addition, we have developed 5 RenMice^TM (RenMab^TM and RenLite^®)-based fully human antibody discovery platforms to meet the demands for antibody drugs against challenging targets or in different modalities, such as mAbs, BsAbs, bispecific ADCs, GPCR-targeted antibodies, and TCR-mimic antibodies. Biocytogen’s Project Integrum develops antibody assets not only for 1000+ extracellular targets but also many intracellular targets, accelerating the development of novel medicines. Whether you need to evaluate your novel immunotherapies, to co-develop new drugs, or to license-in antibody assets, we are happy to discuss the collaboration opportunities with you!

The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. SITC is a 501(c)(3) not-for-profit medical professional society of influential research scientists, physician scientists, clinicians, patients, patient advocates, government representatives and industry leaders dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word “cure” a reality for cancer patients everywhere.